Skip to main content

Market Overview

Global Blood Therapeutics Q1 Earnings Miss Estimates On Disappointing Sales For Its Sickle-Cell Disease Drug

Global Blood Therapeutics Q1 Earnings Miss Estimates On Disappointing Sales For Its Sickle-Cell Disease Drug
  • Global Blood Therapeutics Inc (NASDAQ: GBT) reported a Q1 EPS loss of ($1.21) wider than the anticipated loss estimate of $1.01.
  • Q1 sales of $39.04 million well below the consensus of $43.00 million, all of which stemmed from sickle-cell disease drug, Oxbryta.
  • Revenues increased 177% Y/Y, but on a sequential basis, sales decreased 5%, driven primarily by lower inventory levels and a higher gross-to-net adjustment, partially offset by patient demand.
  • The company blamed the disappointing performance for Oxbryta on COVID-19. It said there were fewer interactions with healthcare providers and patients in the first quarter due to the increased number of cases of COVID-19 in the U.S. As a result, new prescriptions for Oxbryta weren't as high as anticipated.
  • However, the company thinks this is only a short-term problem. It expects that new prescription volume will increase and even top pre-COVID-19 levels in the future.
  • The company said that it's on track to kick off two pivotal late-stage studies of another sickle-cell disease drug, inclacumab, by mid-2021.
  • It also expects to soon submit for U.S. approval to expand the label for Oxbryta to include treating kids ages 4 to 11 who have sickle-cell disease.
  • Analyst reaction after the earnings:
    • Piper Sandler lowered the Global Blood Therapeutics price target to $45 from $50 and kept a Neutral rating on the shares.
    • The company reported Q1 Oxbryta revenue of $39M, a sequential decline that was "perhaps not unexpected" given prior guidance, Catanzaro tells investors in a research note. The analyst believes fiscal 2021 numbers likely need to come down further once again since the challenging commercial dynamics "could persist for Oxbryta in perpetuity."
    • Roth Capital maintains Buy on GBT but lowered price target to $124 from $128.
    • Canaccord Genuity maintains a Hold rating on the stock with a price target cut from $45 to $40.
  • Price Action: GBT shares are down 4.8% at $37.9 during the market trading session on the last check Thursday.

Latest Ratings for GBT

May 2021Canaccord GenuityMaintainsHold
May 2021Roth CapitalMaintainsBuy
Apr 2021SVB LeerinkInitiates Coverage OnOutperform

View More Analyst Ratings for GBT
View the Latest Analyst Ratings


Related Articles (GBT)

View Comments and Join the Discussion!

Posted-In: Biotech Earnings News Guidance Health Care Price Target Analyst Ratings General

Latest Ratings

ALTJMP SecuritiesMaintains53.0
NGACColliers SecuritiesInitiates Coverage On15.0
SAGEWilliam BlairDowngrades62.0
TALMorgan StanleyDowngrades21.5
XJP MorganAssumes41.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at